Teriparatide: A recombinant human parathyroid hormone fragment with anabolic actions for treatment of osteoporosis (PDF)

Medications currently available to treat osteoporosis slow the rate of bone loss primarily by reducing bone resorption. The purported advantage of the anabolic agent teriparatide is that it actually promotes new bone growth. Clinical trials have shown the drug to be effective for vertebral fracture prevention in postmenopausal women at high risk. Additional evidence is accumulating to support teriparatide's use in other populations (including men) with osteoporosis. This injectable is likely to receive FDA approval in the second half of this year.

Related Content

Advertisement

---

FDA Approves Second Biosimilar of Actemra

March 7th 2024

Article

The new biosimilar, Tyenne, was approved in both an IV and a subcutaneous forms to treat inflammatory conditions such as arthritis.

---

Celltrion USA Seeks Approval for Actemra Biosimilar

January 29th 2024

Article

Celltrion’s application is based on data from a phase 3 trial of patients with rheumatoid arthritis comparing its biosimilar with Actemra.

---

FDA Approves First Biosimilar of Arthritis Med Actemra

October 2nd 2023

Article

Biogen is still evaluating launch timeline for Tofidence, and information on pricing will be available closer to launch.

---

FDA Approves First Nonprescription Oral Contraceptive

July 13th 2023

Article

Opill will be available in stores and online in the first quarter of 2024.

---

FDA Schedules Advisory Committee Meeting for OTC Contraceptive

March 29th 2023

Article

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

---

Hyrimoz, a High-Concentration Humira Biosimilar, Approved by FDA

March 22nd 2023

Article

Sandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.

Related Content

Advertisement

---

FDA Approves Second Biosimilar of Actemra

March 7th 2024

Article

The new biosimilar, Tyenne, was approved in both an IV and a subcutaneous forms to treat inflammatory conditions such as arthritis.

---

Celltrion USA Seeks Approval for Actemra Biosimilar

January 29th 2024

Article

Celltrion’s application is based on data from a phase 3 trial of patients with rheumatoid arthritis comparing its biosimilar with Actemra.

---

FDA Approves First Biosimilar of Arthritis Med Actemra

October 2nd 2023

Article

Biogen is still evaluating launch timeline for Tofidence, and information on pricing will be available closer to launch.

---

FDA Approves First Nonprescription Oral Contraceptive

July 13th 2023

Article

Opill will be available in stores and online in the first quarter of 2024.

---

FDA Schedules Advisory Committee Meeting for OTC Contraceptive

March 29th 2023

Article

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

---

Hyrimoz, a High-Concentration Humira Biosimilar, Approved by FDA

March 22nd 2023

Article

Sandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.